Number of issued patents.

No definition available.

Name:	txmd_NumberOfIssuedPatents
Namespace Prefix:	txmd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

INTANGIBLE ASSETS, NET (Details Narrative)	3 Months Ended		12 Months Ended
INTANGIBLE ASSETS, NET (Details Narrative)	Dec. 31, 2020 USD ($) Number	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) Number	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets (Excluding Goodwill) \| $	$ 500,000	$ 600,000	$ 1,131,776	$ 78,864
Amortization of Intangible Assets \| $			$ 269,546	$ 197,593	$ 112,474
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life			20 years
Domestic US Patents
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	38		38
Foreign Patents Member
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	39		39
Domestic Patents BIJUVA
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	15		15
Foreign Patents BIJUVA
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	9		9
Domestic Patents Non-Approved Bijuva [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	3		3
Domestic US Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	12		12
Domestic US Utility Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	10		10
Domestic US Design Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	2		2
Foreign Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	18		18
Foreign Utility Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	8		8
Foreign Design Patents IMVEXXY
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	10		10
Domestic Utility Patent Topical Cream Candidates [Member]
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	1		1
Domestic Utility Patent Transdermal Patch
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	1		1
Foreign Utility Patent Transdermal Patch
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	8		8
Domestic Utility Patent TX009HR
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	3		3
Domestic Patents Progesterone Formulations
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	2		2
Foreign Patents Progesterone Formulations
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	4		4
Domestic Utility Patent Opera
Finite-Lived Intangible Assets [Line Items]
Number of issued patents	1		1